Here is what the page “Astellas Resumes Gene Therapy Development for XLMTM Following Clinical Trial Overhaul | No” contains. Astellas is relaunching its clinical pursuit of AT132, an experimental gene therapy designed to treat X-linked myotubular myopathy (XLMTM), a rare and deva... Astellas is relaunching its clinical pursuit of AT132, an experimental gene therapy designed to treat X-linked myotubular myopathy (XLMTM), a rare and devastating genetic muscle disorder in young boys. This development marks a significant shift in strategy for the pharmaceutical company, which had previously paused trials after the program suffered a series of tragic patient deaths three years ago.
The original clinical trials were halted due to safety concerns that highlighted the extreme risks associated with advanced gene editing technologies. Moving forward with a revised clinical protocol, Astellas aims to balance the urgent need for therapeutic innovation with rigorous safety standards. The full version stays on the original page, which this listing opens directly.